Article
-TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties- -Tranquis plans to start a Phase 2 trial in ALS by the end of 2022- Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases,…
Read MoreConfirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some…
Read More
STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4 inhibition. STI-1558 is also a Cathepsin L inhibitor, which may block effective viral entry into host cells without accelerating viral mutations and could work in conjunction with…
Read More
Durable responses achieved in highly refractory patients as monotherapy (one patient with relapsed squamous cell lung cancer) and in combination with pembrolizumab (several subjects with relapsed squamous cell carcinoma of the anal canal and head and neck squamous cell carcinoma) Dose escalation portion of the study has completed and recommended dose declared, as monotherapy and…
Read More
LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients New “Trial in Progress” Abstract at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Details LEADER’s Primary Objective to Determine the Proportion of Patients Possessing Actionable…
Read More
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working…
Read More
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of 6.9 months and median overall survival of 15.4 months Treatment led to depletion of immunosuppressive myeloid-derived suppressor cells within the tumor microenvironment, suggesting bavituximab may synergistically combine with checkpoint inhibitors Excerpt…
Read More
The Phase 3 ACTIV-1 Immune Modulators study was sponsored by the National Institutes of Health as part of the ACTIV initiative Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19 Safety profile of Orencia remained consistent, with no new safety signals reported Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS…
Read More
Partnership will Enable Accuray to Use Limbus’ Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency Excerpt from the Press Release: SUNNYVALE, Calif. and SASKATCHEWAN, Canada, June 2, 2022 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus’…
Read More
Excerpt from the Press Release: Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD) BRISBANE, Calif., May 24, 2022 – Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented…
Read More